Solventum Corporation (SOLV) is an independent healthcare company with a market cap of $12.4 billion, delivering innovative solutions in Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration segments globally.

SOLV stock has outperformed the S&P 500 Index, rising 21.4% over 52 weeks. However, YTD growth is 8.1%, trailing SPX’s 9.7%. Solventum also surpassed the Health Care Select Sector SPDR Fund’s 10.8% decline in the same period.

Shares of Solventum rose 2% after reporting Q2 2025 adjusted EPS of $1.69 and revenue of $2.2 billion, exceeding Wall Street estimates. The increase was driven by robust MedSurg segment sales, leading to a full-year adjusted EPS guidance of $5.80 – $5.95.

Analysts forecast SOLV’s adjusted EPS to decrease 11.9% year-over-year to $5.90 for the fiscal year ending in December 2025. The consensus rating from 13 analysts is a “Moderate Buy,” with one “Strong Buy” rating.

Piper Sandler raised Solventum’s price target to $94 on Aug. 8, maintaining an “Overweight” rating. The stock is currently trading below the mean price target of $87.12, with a Street-high target of $103 suggesting a 44.2% potential upside.

Read more at Yahoo Finance: Do Wall Street Analysts Like Solventum Stock?